Impact of fibrinogen-to-albumin ratio on the long-term prognosis of patients with advanced HER2-negative gastric cancer receiving immunochemotherapy

Table 6 Adverse events associated with sintilimab plus chemotherapy in gastric cancer patients, n (%)

Variables	Low FAR (n = 123)	High FAR (n = 137)	χ2	P value
All grades: Anemia	72 (58.54)	84 (61.31)	0.21	0.648
All grades: Leukopenia	68 (55.28)	80 (58.39)	0.26	0.613
All grades: Neutropenia	48 (39.02)	55 (40.15)	0.03	0.854
All grades: Thrombocytopenia	35 (28.46)	43 (31.39)	0.27	0.607
All grades: Fatigue	35 (28.46)	45 (32.85)	0.59	0.444
All grades: Nausea	33 (26.83)	42 (30.66)	0.46	0.496
All grades: Hand-foot syndrome	32 (26.02)	38 (27.74)	0.10	0.755
All grades: Elevated ALT	30 (24.39)	34 (24.82)	0.01	0.936
All grades: Elevated AST	30 (24.39)	32 (23.36)	0.04	0.845
All grades: Pyrexia	28 (22.76)	32 (23.36)	0.01	0.910
All grades: Diarrhea	27 (21.95)	33 (24.09)	0.17	0.683
All grades: Hypertension	20 (16.26)	27 (19.71)	0.52	0.471
All grades: Pneumonitis	18 (14.63)	22 (16.06)	0.10	0.751
All grades: Proteinuria	12 (9.76)	18 (13.14)	0.73	0.394
All grades: Mucositis	10 (8.13)	15 (10.95)	0.59	0.441
≥ 3 grades: Anemia	18 (14.63)	22 (16.06)	0.10	0.751
≥ 3 grades: Leukopenia	15 (12.20)	20 (14.60)	0.32	0.571
≥ 3 grades: Neutropenia	15 (12.20)	18 (13.14)	0.02	0.880
≥ 3 grades: Thrombocytopenia	12 (9.76)	16 (11.68)	0.05	0.576
≥ 3 grades: Fatigue	12 (9.76)	20 (14.60)	0.05	0.820
≥ 3 grades: Diarrhea	8 (6.50)	12 (8.76)	0.46	0.496
≥ 3 grades: Nausea	8 (6.50)	10 (7.30)	0.06	0.801
≥ 3 grades: Elevated ALT	5 (4.07)	7 (5.11)	0.16	0.689
≥ 3 grades: Elevated AST	4 (3.25)	7 (5.11)	0.55	0.458
≥ 3 grades: Hand-foot syndrome	4 (3.25)	5 (3.65)	0.03	0.861
≥ 3 grades: Hypertension	3 (2.45)	4 (2.92)	0.06	0.811
≥ 3 grades: Pneumonitis	3 (2.45)	3 (2.19)	0.02	0.894
≥ 3 grades: Mucositis	0 (0.00)	0 (0.00)	-	-
≥ 3 grades: Pyrexia	0 (0.00)	0 (0.00)	-	-
≥ 3 grades: Proteinuria	0 (0.00)	0 (0.00)	-	-

FAR: Fibrinogen-to-albumin ratio; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase.